Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Short-term Investments (2020 - 2024)

Historic Short-term Investments for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2024 value amounting to $10.2 million.

  • Xeris Biopharma Holdings' Short-term Investments fell 4871.92% to $10.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.2 million, marking a year-over-year decrease of 4871.92%. This contributed to the annual value of $5.0 million for FY2023, which is N/A changed from last year.
  • Xeris Biopharma Holdings' Short-term Investments amounted to $10.2 million in Q3 2024, which was down 4871.92% from $20.0 million recorded in Q2 2024.
  • Xeris Biopharma Holdings' 5-year Short-term Investments high stood at $96.2 million for Q4 2020, and its period low was $5.0 million during Q4 2023.
  • Its 5-year average for Short-term Investments is $29.0 million, with a median of $24.7 million in 2024.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 7215.97% in 2022, then skyrocketed by 11277.99% in 2023.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Short-term Investments stood at $96.2 million in 2020, then crashed by 63.45% to $35.2 million in 2021, then tumbled by 73.48% to $9.3 million in 2022, then crashed by 46.35% to $5.0 million in 2023, then surged by 103.32% to $10.2 million in 2024.
  • Its last three reported values are $10.2 million in Q3 2024, $20.0 million for Q2 2024, and $24.7 million during Q1 2024.